Evidence map›Paper›PMID 39677074›Full record

ArticleCureus2024

Hemophagocytic Lymphohistiocytosis Secondary to Miliary Tuberculosis in a Resource-Limited Setting: A Case Report.

Arthur E McKinnon

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Arthur E McKinnonInternal Medicine, Rob Ferreira Hospital, Nelspruit, ZAF.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophagocytic lymphohistiocytosis is a rare life-threatening condition, with a high mortality rate, characterized by a dysfunctional immune response resulting in multi-organ damage. The secondary or sporadic form of the disease can be triggered by a multitude of infections, malignancies, and autoimmune disorders. Tuberculosis is commonly involved as a trigger for hemophagocytic lymphohistiocytosis. In a rare case, a 52-year-old gentleman with advanced human immunodeficiency virus (HIV) and disseminated tuberculosis (TB) developed secondary hemophagocytic lymphohistiocytosis. This patient was successfully treated with the 1994 hemophagocytic lymphohistiocytosis treatment protocol at a hospital in a rural province in South Africa. TB, a treatable condition, remains the most lethal disease in South Africa. This case highlights another severe complication of TB. Despite the widespread rollout of antiretroviral treatment, HIV still remains South Africa's largest epidemic. This case emphasizes the need for physicians, treating people living with HIV infection and TB, to have a high index of suspicion in the appropriate clinical situation for hemophagocytic lymphohistiocytosis. Improved outcomes are possible for these cases when diagnosed and treated timely and correctly.

Indexed as

advanced hiv diseasehemophagocytic lymphohistiocytosishuman immunodeficiency virushyperferritinemiatuberculosis

Identifiers

PMID39677074
PMCPMC11646641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.